[Long-term efficacy and predictors of response to infliximab in Korean patients with Crohn's disease].

[1]  J. Shim,et al.  [Clinical outcome of treatment with infliximab in Crohn's disease: a single-center experience]. , 2013, The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi.

[2]  A. Ford,et al.  Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn's disease: a large single centre experience. , 2012, Journal of Crohn's & colitis.

[3]  T. Einarson,et al.  Hospitalization and surgical rates in patients with Crohn's disease treated with infliximab: a matched analysis , 2011, Pharmacoepidemiology and drug safety.

[4]  W. Reinisch,et al.  Review article: infliximab for Crohn’s disease treatment – shifting therapeutic strategies after 10 years of clinical experience , 2011, Alimentary pharmacology & therapeutics.

[5]  P. Rutgeerts,et al.  Infliximab, azathioprine, or combination therapy for Crohn's disease. , 2010, The New England journal of medicine.

[6]  M. Picco.  Mucosal Healing Predicts Sustained Clinical Remission in Patients With Early-Stage Crohn's Disease , 2010 .

[7]  P. Rutgeerts,et al.  Mucosal healing predicts long‐term outcome of maintenance therapy with infliximab in Crohn's disease , 2009, Inflammatory bowel diseases.

[8]  Eun Hee Kim,et al.  [Efficacy of infliximab in the treatment of korean patients with crohns disease]. , 2009, The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi.

[9]  K. Van Steen,et al.  Long-term outcome of treatment with infliximab in 614 patients with Crohn’s disease: results from a single-centre cohort , 2008, Gut.

[10]  M. Vatn,et al.  Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[11]  J. S. Kim,et al.  [Efficacy and safety of treatment with infliximab in Crohn's disease-the experience of single center in Korea]. , 2005, The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi.

[12]  M. Bala,et al.  Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. , 2005, Gastroenterology.

[13]  L. Beaugerie,et al.  Impact of the increasing use of immunosuppressants in Crohn’s disease on the need for intestinal surgery , 2005, Gut.

[14]  P. Rutgeerts,et al.  Infliximab maintenance therapy for fistulizing Crohn's disease. , 2004, The New England journal of medicine.

[15]  P. Rutgeerts,et al.  Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. , 2004, Gastroenterology.

[16]  F. Carbonnel,et al.  Long-Term Evolution of Disease Behavior of Crohn's Disease , 2002, Inflammatory bowel diseases.

[17]  S. Hanauer,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[18]  A. Zinsmeister,et al.  The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. , 2001, Gastroenterology.

[19]  M. Kamm,et al.  Infliximab for the treatment of fistulas in patients with Crohn'S disease. , 1999, Gastroenterology.

[20]  S. Targan,et al.  A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease , 1997 .

[21]  S. Targan,et al.  A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. , 1997, The New England journal of medicine.